The phospholipase A2 group IIA (PLA2G2A) antibody targets a secreted enzyme belonging to the phospholipase A2 superfamily, which hydrolyzes phospholipids to release fatty acids like arachidonic acid—a precursor for pro-inflammatory mediators. Primarily expressed in immune cells, gastrointestinal tissues, and secretory glands, PLA2G2A plays roles in inflammation, host defense, and lipid metabolism. Its dysregulation is linked to diseases including atherosclerosis, rheumatoid arthritis, and cancers (e.g., colorectal, prostate). PLA2G2A antibodies are essential tools for detecting this protein in research applications like Western blotting, immunohistochemistry, and ELISA. Studies using these antibodies have revealed PLA2G2A's dual roles in cancer, acting as either a tumor suppressor or promoter depending on context, and its potential as a biomarker for disease progression or therapeutic targeting. Commercial PLA2G2A antibodies vary in clonality, epitope specificity, and host species, requiring validation for experimental reliability. Ongoing research aims to clarify its mechanisms in inflammation-related pathologies and explore clinical applications, such as modulating PLA2G2A activity in autoimmune disorders or leveraging its expression patterns for diagnostic purposes.